Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-ranging study of brepocitinib cream in mild to moderate atopic dermatitis
jRCT2080224889Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2019
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of brepocitinib in atopic dermatitis (AD) (7 arms), sponsored by Pfizer. Primary endpoint: Percent change from baseline in EASI score at Week 6. Started Sep 2019; status: completed.
02
Drugs
brepocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2080224889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224889.